nach oben

Diabetologia

Erschienen in:

01.07.2006 | Article

High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis

verfasst von: D. A. McClain, D. Abraham, J. Rogers, R. Brady, P. Gault, R. Ajioka, J. P. Kushner

Erschienen in: Diabetologia | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The prevalence and mechanisms of diabetes in hereditary haemochromatosis are not known. We therefore measured glucose tolerance, insulin secretory capacity and insulin sensitivity in adults with haemochromatosis.

Subjects and methods

Subjects recruited from referrals to a haemochromatosis clinic underwent OGTT and frequently sampled IVGTT. A chart review of former clinic patients was also performed.

Results

The prevalence of diabetes (23%) and IGT (30%) was increased in haemochromatosis compared with matched control subjects (0% diabetes and 14% IGT). Subjects with haemochromatosis and diabetes were overweight (14%) or obese (86%). The prevalence of diabetes, as determined by chart review of fasting glucose values, in subjects who had haemochromatosis and were in the 40–79 years age range was 26%. Overall, patients with haemochromatosis and control subjects had similar values for acute insulin response to glucose and insulin sensitivity. However, patients with haemochromatosis and IGT had a 68% decrease in acute insulin response to glucose (p<0.02) compared with those with NGT. They were not insulin-resistant, exhibiting instead a 62% increase in insulin sensitivity (NS). Haemochromatosis subjects with diabetes exhibited further declines in acute insulin response to glucose, insulin resistance, or both.

Conclusions/interpretation

Diabetes and IGT are common in haemochromatosis, justifying screening for diabetes and therapeutic phlebotomy. The major abnormality associated with IGT is decreased insulin secretory capacity. Diabetes is usually associated with obesity and concomitant insulin resistance.

Edwards C (1999) Hemochromatosis. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM (eds) Wintrobe’s Clinical Hematology. Williams & Wilkins, Baltimore, Massachusetts, pp 1056–1070

Bothwell THCR, Motulsky AG (1995) Hemochromatosis. In: Scriver CR, Beaudet A, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 2237–2269

Feder JN, Gnirke A, Thomas W et al (1996) A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13:399–408PubMedCrossRef

Feder JN, Tsuchihashi Z, Irrinki A et al (1997) The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 272:14025–14028PubMedCrossRef

Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C (2005) Hepcidin is decreased in TFR2 hemochromatosis. Blood 105(4):1803–1806PubMedCrossRef

Nemeth E, Tuttle MS, Powelson J et al (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090–2093PubMedCrossRef

Edwards CQ, Dadone MM, Skolnick MH, Kushner JP (1982) Hereditary haemochromatosis. Clin Haematol 11:411–435PubMed

Buysschaert M, Paris I, Selvais P, Hermans MP (1997) Clinical aspects of diabetes secondary to idiopathic haemochromatosis in French-speaking Belgium. Diabetes Metab 23:308–313PubMed

Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y (1997) Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med 127:105–110PubMed

10.

Hramiak IM, Finegood DT, Adams PC (1997) Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med 20:110–118PubMed

11.

Merkel PA, Simonson DC, Amiel SA et al (1988) Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 318:809–814PubMedCrossRef

12.

Mendler MH, Turlin B, Moirand R et al (1999) Insulin resistance-associated hepatic iron overload. Gastroenterology 117:1155–1163PubMedCrossRef

13.

Rossetti L, Giaccari A, DeFronzo RA (1990) Glucose toxicity. Diabetes Care 13:610–630PubMedCrossRef

14.

Bugianesi E, Manzini P, D’Antico S et al (2004) Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39:179–187PubMedCrossRef

15.

Cooksey RC, Jouihan HA, Ajioka RS et al (2004) Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology 145:5305–5312PubMedCrossRef

16.

Adams PC, Reboussin DM, Barton JC et al (2005) Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352:1769–1778PubMedCrossRef

17.

Guttridge MG, Thompson J, Worwood M, Darke C (1998) Rapid detection of genetic mutations associated with haemochromatosis. Vox Sang 75:253–256PubMedCrossRef

18.

Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef

19.

Saad MF, Steil GM, Riad-Gabriel M et al 1997 Method of insulin administration has no effect on insulin sensitivity estimates from the insulin-modified minimal model protocol. Diabetes 46:2044–2048PubMedCrossRef

20.

Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN (2003) MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5:1003–1015PubMedCrossRef

21.

Kenny S, Aubert RE, Geiss LS (1995) Prevalence and incidence of non-insulin-dependent diabetes. In: Health NIo, Diseases NIoDaDaK (eds) National Diabetes Data Group. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, pp 47–68

22.

Bulaj ZJ, Ajioka RS, Phillips JD et al (2000) Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 343:1529–1535PubMedCrossRef

23.

Kahn SE, Prigeon RL, McCulloch DK et al (1993) Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663–1672PubMedCrossRef

24.

Chen H, Sullivan G, Quon MJ (2005) Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 54:1914–1925PubMedCrossRef

25.

Ajioka RS, Kushner JP (2002) Hereditary hemochromatosis. Semin Hematol 39:235–241PubMedCrossRef

26.

Kwan T, Leber B, Ahuja S, Carter R, Gerstein HC (1998) Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene. Clin Invest Med 21:251–257PubMed

27.

Moczulski DK, Grzeszczak W, Gawlik B (2001) Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care 24:1187–1191PubMedCrossRef

28.

Braun J, Donner H, Plock K, Rau H, Usadel KH, Badenhoop K (1998) Hereditary haemochromatosis mutations (HFE) in patients with type II diabetes mellitus. Diabetologia 41:983–984PubMedCrossRef

29.

Dubois-Laforgue D, Caillat-Zucman S, Djilali-Saiah I et al (1998) Mutations in HFE, the hemochromatosis candidate gene, in patients with NIDDM. Diabetes Care 21:1371–1372PubMedCrossRef

30.

Frayling T, Ellard S, Grove J, Walker M, Hattersley AT (1998) C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes. Lancet 351:1933–1934PubMedCrossRef

31.

Halsall DJ, McFarlane I, Luan J, Cox TM, Wareham NJ (2003) Typical type 2 diabetes mellitus and HFE gene mutations: a population-based case–control study. Hum Mol Genet 12:1361–1365PubMedCrossRef

32.

Sampson MJ, Williams T, Heyburn PJ et al (2000) Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes. J Lab Clin Med 135:170–173PubMedCrossRef

33.

Conte D, Manachino D, Colli A et al (1998) Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med 128:370–373PubMed

34.

Ellervik C, Mandrup-Poulsen T, Nordestgaard BG et al (2001) Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 358:1405–1409PubMedCrossRef

35.

Valenti L, Conte D, Piperno A et al (2004) The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J Med Genet 41:946–950PubMedCrossRef

36.

Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP (1996) Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 335:1799–1805PubMedCrossRef

37.

Van Lerberghe S, Hermans MP, Dahan K, Buysschaert M (2002) Clinical expression and insulin sensitivity in type 2 diabetic patients with heterozygous mutations for haemochromatosis. Diabetes Metab 28:33–38PubMed

38.

Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB (2004) Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291:711–717PubMedCrossRef

39.

Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF (2003) Potential role of increased iron stores in diabetes. Am J Med Sci 325:332–339PubMedCrossRef

40.

Tuomainen TP, Nyyssonen K, Salonen R et al (1997) Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. Diabetes Care 20:426–428PubMedCrossRef

41.

Mangiagli A, Italia S, Campisi S (1998) Glucose tolerance and beta-cell secretion in patients with thalassemia major. J Pediatr Endocrinol Metab 11:985–986PubMed

42.

Pelot D, Zhou XJ, Carpenter P, Vaziri ND (1998) Effects of experimental hemosiderosis on pancreatic tissue iron content and structure. Dig Dis Sci 43:2411–2414PubMedCrossRef

43.

Andrews NC (1999) The iron transporter DMT1. Int J Biochem Cell Biol 31:991–994PubMedCrossRef

44.

MacDonald MJ, Cook JD, Epstein ML, Flowers CH (1994) Large amount of (apo)ferritin in the pancreatic insulin cell and its stimulation by glucose. FASEB J 8:777–781PubMed

45.

Cario H, Holl RW, Debatin KM, Kohne E (2003) Insulin sensitivity and beta-cell secretion in thalassemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. Eur J Pediatr 162:139–146PubMed

46.

Fernandez-Real JM, Lopez-Bermejo A, Ricart W (2002) Cross-talk between iron metabolism and diabetes. Diabetes 51:2348–2354PubMedCrossRef

47.

Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc’h A, Deugnier Y (2001) Histologic features of the liver in insulin resistance-associated iron overload. A study of 139 patients. Am J Clin Pathol 116:263–270PubMedCrossRef

48.

Dubois-Laforgue D, Caillat-Zucman S, Boitard C, Timsit J (2000) Clinical characteristics of type 2 diabetes in patients with mutations of HFE. Diabetes Metab 26:65–68PubMed

49.

Caronia S, Taylor K, Pagliaro L et al (1999) Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30:1059–1063PubMedCrossRef

Titel: High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis
verfasst von: D. A. McClain
D. Abraham
J. Rogers
R. Brady
P. Gault
R. Ajioka
J. P. Kushner
Publikationsdatum: 01.07.2006
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 7/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0200-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Subjects and methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2006

PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice

Is grand multiparity associated with an increased risk of dysglycaemia?

Iron and glucose homeostasis: new lessons from hereditary haemochromatosis

What determines the cost-effectiveness of diabetes screening?

Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis